ASXL1 Inhibitors
ASXL1 inhibitors belong to a class of compounds specifically designed to target and modulate the activity of the ASXL1 gene. ASXL1, or Additional Sex Combs-Like 1, is a vital gene that plays a crucial role in regulating gene expression and chromatin modification. Chromatin is a complex of DNA and proteins, and its structure can be modified to control the accessibility of genes for transcription, thus influencing gene expression. ASXL1 is a key player in this process, as it acts as a cofactor for epigenetic regulators, particularly in the Polycomb Repressive Complex 2 (PRC2) and the Mixed Lineage Leukemia (MLL) complex. These complexes are responsible for adding or removing specific chemical marks, such as methyl groups, on histone proteins, thereby influencing gene activation or repression.
ASXL1 inhibitors are designed to interact with ASXL1 protein or its associated complexes in various ways. By disrupting the function of ASXL1, these inhibitors modulate the epigenetic landscape of cells, leading to altered gene expression patterns. This can have significant implications in various biological processes and disease states, as aberrant epigenetic regulation is often associated with conditions such as cancer and developmental disorders. Research into ASXL1 inhibitors is an ongoing area of study, aimed at uncovering the full spectrum of their effects on epigenetic regulation and gene expression.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Panobinostat | 404950-80-7 | sc-208148 | 10 mg | $200.00 | 9 | |
Panobinostat is another histone deacetylase inhibitor with a similar mechanism of action to vorinostat. It could potentially influence ASXL1 expression through alterations in chromatin structure and gene expression. | ||||||
Belinostat | 414864-00-9 | sc-269851 sc-269851A | 10 mg 100 mg | $156.00 $572.00 | ||
Belinostat is also a histone deacetylase inhibitor, and it works by increasing acetylation levels of histones, potentially affecting the chromatin state and expression of ASXL1. | ||||||
Valproic Acid | 99-66-1 | sc-213144 | 10 g | $87.00 | 9 | |
Valproic acid has histone deacetylase inhibitory activity, and its alteration of chromatin structure can influence the expression of various genes, potentially including ASXL1. | ||||||
RG 108 | 48208-26-0 | sc-204235 sc-204235A | 10 mg 50 mg | $131.00 $515.00 | 2 | |
RG108 is a DNA methyltransferase inhibitor, and by inhibiting DNA methylation, it can alter gene expression patterns, possibly affecting ASXL1 expression. | ||||||
Homocysteine | 6027-13-0 | sc-507315 | 250 mg | $195.00 | ||
S-(5'-Adenosyl)-L-homocysteine is a product of S-adenosylmethionine-dependent methylation reactions, and it can act as an inhibitor of methyltransferases, potentially leading to alterations in gene expression and chromatin state that affect ASXL1. | ||||||
Disulfiram | 97-77-8 | sc-205654 sc-205654A | 50 g 100 g | $53.00 $89.00 | 7 | |
Disulfiram has been shown to have various biological activities, and it has been reported to inhibit the proteasome, which could potentially lead to reduced degradation of proteins that regulate ASXL1 expression, indirectly influencing ASXL1 levels. | ||||||
(±)-JQ1 | 1268524-69-1 | sc-472932 sc-472932A | 5 mg 25 mg | $231.00 $863.00 | 1 | |
JQ1 is a small molecule that inhibits BET bromodomains, which are involved in recognizing acetylated lysine residues on histones. By inhibiting BET bromodomains, JQ1 can affect gene expression and potentially downregulate ASXL1 expression. | ||||||
GSK126 | 1346574-57-9 | sc-490133 sc-490133A sc-490133B | 1 mg 5 mg 10 mg | $92.00 $243.00 $306.00 | ||
GSK126 is a small molecule inhibitor of EZH2, a component of the polycomb repressive complex 2 (PRC2) that mediates trimethylation of histone H3 at lysine 27 (H3K27me3). By inhibiting EZH2, GSK126 can alter chromatin states and potentially affect ASXL1 expression. | ||||||